

— OFFICIALLY LICENSED —

BEST OF ASCO®

2016 ANNUAL MEETING

www.asco.org



SLS
SLOVENSKÁ LEKÁRSKA SPOLOČNOSŤ

SOLEN
MEDICAL EDUCATION

PROGRAM

Slovak Oncology Society

Best of ASCO® Conference 2016

A program licensed by the American Society of Clinical Oncology, Inc.

8. ročník / 8th Annual

1th July 2016 | Holiday Inn, Bratislava, Slovakia

Place: Holiday Inn, Bratislava

Date: 1st July 2016

Official language: Slovak

8.00 – 8.30 **Registration**

8.30 – 8.35 **Welcome**
President of Slovak Oncology Society, Tomáš Šálek

I. Gastrointestinal Cancer Session

Chairmen: Tomáš Šálek, Juraj Detvay

(8.35 – 9.40)

8.35 – 8.55

1. Gastrointestinal cancer (Colorectal) (Juraj Detvay, FNsP Nitra)

1. Abstract # 3504 **Impact of primary (1o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).** (Alan P. Venook)
2. Abstract # 3507 **CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer – Results of the UK ColoRectal Endoscopic Stenting Trial (CREST).** (James Hill)
3. Abstract # 3511 **The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.** (Jeanne Tie)
4. Abstract # 3512 **FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized study—Prodige 14 – Accord 21 (METHEP-2), a UNICANCER GI trial.** (Marc Ychou)
5. Abstract # 3503 **NCI9673: A Multi-Institutional ETCTN Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA).** (Van Karlyle Morris II)

8.55 – 9.15

2. Gastrointestinal (Non-Colorectal) Cancer (Tomáš Šálek, NOÚ Bratislava)

1. Abstract # LBA4001 **FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.** (Salah-Eddin Al-Batran)
2. Abstract # 4003 **Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802 (Alliance).** (Ghassan K. Abou-Alfa)

3. Abstract # 4005 **NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate.** (Jonathan R. Strosberg)
4. Abstract # 4000 **A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.** (Marcel Verheij)
5. Abstract # **LBA4006 ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.** (John P. Neoptolemos)

9.15 – 9.40

Discussion

II. Head&Neck Cancer / Melanoma&Skin Cancers Session

Chairmen: Juraj Beniak, Pavol Dubinský, Róbert Godál

(9.40 – 10.45)

9.40 – 10.00

3. Head&Neck Cancer (Pavol Dubinský, VOÚ Košice)

1. Abstract # LBA2 **A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).** (James R. Perry)
2. Abstract # 6007 **Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.** (Li Zhang)
3. Abstract # 6000 **Induction taxotere platinum 5-FU (TPF) followed by cetuximab-radiotherapy versus concurrent chemo-radiotherapy in patients with N2b-N3 (non operated Stage III-IV) squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial.** (Lionnel Geoffrois)
4. Abstract #6009 **Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.** (Robert L. Ferris)
5. Abstract # 6011 **Preliminary results from KEYNOTE-055: pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).** (Joshua Bauml)

10.00 – 10.20

4. Melanoma&Skin Cancers (Róbert Godál, NOÚ Bratislava)

1. Abstract # 9503 **Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE- 001.** (Caroline Robert)
2. Abstract # 9505 **Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment- naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).** (Jedd D. Wolchok)

3. Abstract # 9506 **Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.** (Georgina V. Long)
4. Abstract # 9504 **Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE- 006.** (Jacob Schachter)
5. Abstract # 9502 **Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.** (Keith T. Flaherty)

10.20 – 10.45 Discussion

10.45 – 11.05 Coffee-Break

III. Lung Cancer&Mesothelioma / Patient and Survivor Care Session

Chairmen: Peter Kasan, Peter Beržinec, Andrea Škripeková

(11.05 – 12.05)

11.05 – 11.25

5. Patient and Survivor Care (Andrea Škripeková, NOÚ Bratislava)

1. Abstract # 10001 **Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials.** (Dawn L. Hershman)
2. Abstract # 10006 **Benefits of Physician Orders for Scope of Treatment (POST) forms on end-of-life care in cancer patients: Insights from the West Virginia registry.** (Mark W. Knestrick)
3. Abstract # 10000 **A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients.** (Ian Kleckner)
4. Abstract # 10003 **Randomized trial of early integrated palliative and oncology care.** (Jennifer S. Temel)
5. Abstract # 10019 **Placebo-controlled phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetron in high emetogenic chemotherapy.** (Kunihiro Matsuzaki)

11.25 – 11.45

6. Lung Cancer (Peter Beržinec, ŠN Sv. Svorada, Nitra)

1. Abstract # 9004 **Local Consolidative Therapy (LCT) Improves Progression-Free Survival (PFS) in Patients with Oligometastatic Non-Small Cell Lung Cancer (NSCLC) who Receive Induction Systemic Therapy (IST): Results of a Multi-Institutional Phase II Randomized Study.** (Daniel Richard Gomez)
2. Abstract # 9012 **A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): LURET study.** (Takashi Seto)
3. Abstract # 108 **Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).** (Alexander E. Drilon)

4. Abstract # 9008 **Primary analysis for alectinib versus crizotinib in ALK-inhibitor naïve ALK positive non-small cell lung cancer (ALK+ NSCLC) in randomized open-label phase III trial (J-ALEX study).** (Hiroshi Nokihara)
5. Abstract # 8500 **Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer.** (Zhongxing X. Liao)
6. Abstract # 8507 **E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets.** (Heather A. Wakelee)
7. Abstract # LBA8505 **Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3) – targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).** (Charles M. Rudin)
8. Abstract # 8504 **CONVERT: An international randomised controlled trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy (RT) schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS) (NCT00433563).** (Corinne Faivre-Finn)

11.45 – 12.05 **Discussion**

12.05 – 13.05 **Lunch**

IV. Genitourinary Cancer / Gynecologic Cancer Session

Chairmen: Vladimír Malec, Michal Mego, Branislav Bystrický (13.05 – 14.10)

13.05 – 13.25

7. Genitourinary Cancer (Michal Mego, NOÚ Bratislava)

1. Abstract # 5006 **Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).** (A. Oliver Sartor)
2. Abstract # 5008 **Phase III non-inferiority study of cabazitaxel C 20 mg/m² (C20) versus 25 mg/m² (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).** (Johann S. De Bono)
3. Abstract # 5001 **A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high-risk prostate cancer: Results of SPCG12.** (Goran Ahlgren)
4. Abstract # 5003 **A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.** (Charles N Catton)
5. Abstract # 5004 **Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).** (Linda J. Patrick-Miller)
6. Abstract # 4506 **Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).** (Toni K. Choueiri)

7. Abstract # LBA4500 **Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.** (Arjun Vasant Balar)

8. Abstract #4503 **Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02).** (Jeurgen E. Gschwend)

13.25 – 13.45

8. Gynecologic Cancer (Branislav Bystrický, FNŠP Trenčín)

1. Abstract # 5501 **Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.** (Jonathan A. Ledermann)

2. Abstract # 5507 **Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS.** (Usha Menon)

3. Abstract # LBA5503 **OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).** (Helen Mackay)

4. Abstract # 5508 **Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG Symptom Benefit Study (SBS).** (Felicia Roncolato)

13.45 – 14.10

Discussion

V. Breast Cancer Session

Chairmen: Mária Wagnerová, Jozef Mardiak, Stanislav Špánik

(14.10 – 15.15)

14.10 – 14.30

9. Breast Cancer – HER2/ER+ (Stanislav Špánik, OÚSA Bratislava)

1. Abstract # LBA1 **A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.** (Paul E. Goss)

2. Abstract # 512 **Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).** (Nicholas C. Turner)

3. Abstract # 507 **PALOMA-2: Primary results from a phase 3 trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).** (Richard S. Finn)

4. Abstract # 500 **Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE).** (Sara A. Hurvitz)

5. Abstract # LBA503 **Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O vs Herceptin.** (Nicholas C. Turner)

14.30 – 14.50

10. Breast Cancer – Triple-Negative / Local Therapy

(Jozef Mardiak, NOÚ Bratislava)

1. Abstract # 1000 **Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.** (Joanne Lorraine Blum)

2. Abstract # 1007 **Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance).** (Armando E. Giuliano)

3. Abstract # 1005 **A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01).** (Atilla Soran)

4. Abstract # LBA509 **Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.** (Aditya Bardia)

14.50 – 15.15

Discussion

15.15 – 15.20

Closing remarks

President of Slovak Oncology Society, Tomáš Šálek

FAREWELL

PRIEZVSKO, MENO, TITUL (čítateľne):
SURNAME, NAME, TITLE (LEGIBLY):

FAKTURAČNÁ ADRESA:

BILLING ADDRESS:

TEL., FAX:

E-MAIL:

REG. Č. SLOVENSKEJ LEKÁRSKEJ KOMORY:

REG. NUMBER OF THE SLOVAK MEDICAL CHAMBER:

REGISTRAČNÝ POPLATOK/REGISTRATION FEE: 10 €

ZÁVÄZNÁ OBJEDNÁVKA UBYTOVANIA V HOTELI HOLIDAY INN (DO 31. 5. 2016)

OBLEGATORY ORDER OF THE ACCOMMODATION IN THE HOLIDAY INN (to 31th May 2016)

(Na základe vyplnenej príhlášky Vám bude obratom zaslaná zľahová táktúra na ubytovanie.)

dvojlôžková izba – **99 €** (cena je uvedená s DPH, zahŕňa ubytovanie na 1 noc, raňajky, miestny poplatok)

Mám záujem o ubytovanie z 30. 6. 2016 na 1. 7. 2016

I would like to book a room from 30th June till 1th July 2016

áno/Yes

nie/No

Mám záujem o ubytovanie z 1. 7. 2016 na 2. 7. 2016

I would like to book a room from 1th July till 2nd July 2016

áno/Yes

nie/No

CHCEM BYŤ UBYTOVANÝ(A) S:

I WOULD LIKE TO SHARE A ROOM WITH:

Týmto dávam súhlas spoločnosti SOLEN s.r.o. na spracovanie mojich osobných údajov, uvedených v tomto dokumente na účel spracovania príhlášok a rozosielanie informácií e-mailov v zmysle zák. č. 122/2013 Z.z. o ochrane osobných údajov. Tento súhlas je možné kedykoľvek odvolať písomnou formou.

I herein give permission to the SOLEN Company for the usage of my personal data that is presented in this document for the purpose of the processing of the application forms and for the distribution of information emails according to the act No. 122/2013. The act No. 482/2002 deals with security of personal data. This permission may be cancelled anytime in writing.

Rezervácia ubytovania je záväzná, zmena je možná bez účtovania storno poplatku do **31. 5. 2016**. Po tomto dátume bude nautčovany 100% storno poplatok.

Reservation of the accommodation is obligatory and the changes of the reservations can be done without any fees until 31th May 2016. After 25th June 2016, there will be charged a 100% cancellation fee.

Vyplnenú príhlášku prosíme zaslať na adresu organizátora pošťou alebo mailom.

Organization: SOLEN, s. r. o., Ambrova 5, 831 01 Bratislava, e-mail: kongres@solen.sk

Please, send completed Application Form to the address of the organizer by mail, or email.
Organizer: SOLEN, s. r. o., Ambrova 5, 831 01 Bratislava, e-mail: kongres@solen.sk

Akceptujeme aj príhlášku cez web stránku spoločnosti SOLEN, s. r. o. na adrese: www.solen.sk v sekcii Kongresy a semináre. Telefonické prihlásenie na podujatie nie je možné. We accept the registration through the web page of organizer SOLEN, s.r.o.: www.solen.sk in the section "Kongresy a semináre". There is no possibility of the registration by phone.

Príhlášky zasielajte najneskôr do **31. 5. 2016** (ubytovanie) alebo do **25. 6. 2016** (účast').
The deadline for application is 31th May 2016 (accommodation) or 25th June 2016 (attendance).

Podpis/signature